Singh, A and Wang, Z and Dissanayaka, T and Das, S and Antony, B, Efficacy and safety of hydroxychloroquine in osteoarthritis: a systematic review and meta-analysis of randomized controlled trials, The Korean Journal of Internal Medicine ISSN 1226-3303 (2021) [Refereed Article]
|PDF (Online first)|
Copyright © 2021 The Korean Association of Internal Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International (CC BY-NC 4.0) License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background/aims: Conventional disease-modifying anti-rheumatic drugs have been trialed in osteoarthritis (OA). Hydroxychloroquine (HCQ), which has shown its effectiveness in rheumatoid arthritis, has been trialed for the treatment of OA; however, its efficacy and safety remain unclear. This systematic review and meta-analysis evaluate efficacy and safety of HCQ for the treatment of OA.
Methods: MEDLINE, EMBASE, and Cochrane Central were searched from inception through June 2020. Two reviewers independently screened for randomized controlled trials (RCTs) comparing HCQ with placebo or other active-comparators for the treatment of knee, hand, or hip OA, extracted data, and performed Cochrane risk of bias assessments.
Results: Six RCTs, four in hand OA, two in knee OA, consisting of 842 patients (436 in HCQ arm, 406 in control arm) were included. RCTs were conducted between 2012 and 2020, one each at UK, Netherlands, Germany, Italy, Iran, and Egypt; follow-up period ranged 24 to 52 weeks. High-quality evidence showed no clinically important pain reduction with HCQ compared to placebo/active-control in hand OA (standardized mean difference [SMD], 0.14; 95% confidence interval [CI], -0.20 to 0.48). Effect on pain reduction in knee and hand OA was small and non-significant (SMD, -0.09; 95% CI, -0.44 to 0.25). High-quality evidence showed no improvement in dysfunction with HCQ compared to placebo in hand OA patients (SMD, 0.08; 95% CI, -0.23 to 0.40). Effect on dysfunction improvement in knee and hand OA was modest and statistically non-significant (SMD, -0.20; 95% CI,-0.57 to 0.18). No improvement in quality of life was observed in hand OA.
Conclusions: HCQ has no benefit in reducing pain and improving physical function in hand or knee OA patients.
|Item Type:||Refereed Article|
|Keywords:||hydroxychloroquine, osteoarthritis, systematic review, meta-analysis, randomized controlled trial|
|Research Division:||Health Sciences|
|Research Group:||Health services and systems|
|Research Field:||General practice|
|Objective Group:||Clinical health|
|Objective Field:||Efficacy of medications|
|UTAS Author:||Singh, A (Mr Ambrish Singh)|
|UTAS Author:||Wang, Z (Mr Zhiqiang Wang)|
|UTAS Author:||Antony, B (Dr Benny Eathakkattu Antony)|
|Web of Science® Times Cited:||5|
|Deposited By:||Menzies Institute for Medical Research|
|Downloads:||8 View Download Statistics|
Repository Staff Only: item control page